Bleomycin Sulfate

For research use only.

Catalog No.S1214 Synonyms: NSC125066

32 publications

Bleomycin Sulfate Chemical Structure

Molecular Weight(MW): 1512.62

Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 357 In stock
USD 170 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Bleomycin Sulfate has been cited by 32 publications

Purity & Quality Control

Choose Selective Antineoplastic and Immunosuppressive Antibiotics Inhibitors

Biological Activity

Description Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.
In vitro

UT-SCC-12A and UT-SCC-12B are both more resistant to Bleomycin sulfate with IC50 of 14.2 nM and 13 nM, respectively. [1] Alveolar macrophages incubated with 0.01 μg/mL to 1μg /mL Bleomycin sulfate for 18 hours secretes significantly more fibroblast growth factor than macrophages incubated without Bleomycin sulfate. Macrophages stimulated with Bleomycin sulfate continues to produce significant amounts of fibroblast growth factor even after Bleomycin sulfate is removed and replaced with fresh (Bleomycin sulfate-free) media. Fibroblast growth factor secretion by Bleomycin sulfate-stimulated alveolar macrophages is inhibited by cycloheximide, and the 5-lipoxygenase inhibitors NDGA (nordihydroguaiaretic acid) and BW755c, indicating not only a requirement for protein synthesis but also for metabolites of the 5-lipoxygenase pathway of arachidonic acid metabolism for full expression of activity. [2] Bleomycin sulfate (400 µg/mL) incubation for 24 hours decreases the viability of NTera-2 cells, and increases caspase-3, -8 and -9 activities, Bax and cytoplasmic cytochrome c levels and decreases Bcl-2 levels. [3] In terms of unstable aberrations, the clastogenic effect of Bleomycin sulfate on ADIPO-P2 cells persists for at least 10 days after exposure. Bleomycin sulfate-induced telomere instability in mammalian cells persists for several generations after exposure. Moreover, the appearance of telomere fusions in Bleomycin sulfate-exposed cells 10 days after treatment suggests that Bleomycin sulfate can induce delayed telomere instability. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
F98 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rH[|DjiJNzMECwJO69dQ>? NFOxWXYzPCCqwrC= MkP6bY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> M2\EcVI3ODh6N{Gx
POLK WT NUfQfXNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTFzLkhihKnDueLCiUGuO:Kh|ryP MlXwNlYxOzF2MEC=
POLK KO Mn7OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzJU|ZYUUN3ME20MlA{6oDLwsJihKkyNjl{wrFOwG0> NVrUOWVtOjZyM{G0NFA>
POLK CD NFrmV|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTVwNUpihKnDueLCiUGuNFDDqM7:TR?= MYeyOlA{OTRyMB?=
RLE/Abca3 NFfW[m9HfW6ldHnvckBCe3OjeR?= M4DHcVAvPMLizszN NU\ZVnQ6OTR2wrDo Ml:2bY5lfWOnczDhJI1wenCqb3zv[4lk[WxiY3jhcodmKG[{b32g[ZBqfGinbHnhcE1tcWunIH3vdpBpd2yxZ4mgeI8h[SC5aXTlMEB{eHKnYXStc5V1KG2xcoDoc4xw\3oEoB?= M2DJS|I2PzZyNUO4
PMCs NGnXW3ZHfW6ldHnvckBCe3OjeR?= MmnINE4y6oDVMtMg{txoN22u MkTQNlTDqGh? NIPvVpRk[XW|ZYOgZUBld3OnLXTldIVv\GWwdDDpcoNz\WG|ZTDpckB1cGVicILveIVqdiCuZY\lcEBw\iClb3zsZYdmdi2LwrC= M1rs[|I2PTl3NkSy
PMCs NHmxWZBHfW6ldHnvckBCe3OjeR?= NH6yd4gxNjMEoN88[{9udA>? NVrB[4h7OjUkgKO3NuKhcA>? MVrpcoR2[2W|IHnuZ5Jm[XOnczDpckB3cW2nboTpckBidmRizsGtV21CKHC{b4TlbY4> M{PXTlI2PTl3NkSy
PMCs M{jQNmZ2dmO2aX;uJGF{e2G7 NU[yO3F7OC5{wrFOwIcwdWx? NGP0Zoo4OiCq Mm[2bY5lfWOnczDk[YNz\WG|ZYOgbY4h[3m2b3vldoF1cW5vODDhcoQhTS2lYXTo[ZJqdiCycn;0[Ylv NIix[|gzPTV7NU[0Ni=>
PMCs MVLGeY5kfGmxbjDBd5NigQ>? NIX4V5YxNjMEoN88[{9udA>? NH20fogyOi9{ND:0PEBp NYH0SnJTcW6lcnXhd4V{KGOnbHygcYloemG2aX;u NYT2Vm9MOjV3OUW2OFI>
IMR-32 MljKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPiTGI4NjYkiKKxNlAhyrWpL33s MUSxNwKJmjR6IHi= MWXJR|UxRTZyINM1[{9udCCjdDD0bIUh\W6mIH;mJFI1KGi{czDv[kBqdmO3YnH0bY9v M2jtW|I2PTN4M{S1
HT1080 MmC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELwNlgyKM7:TR?= NUf4cVBJOjRiaNMg MoXLcIVi\HNidH:gZUBIOi:PIHTlcIF6 NYLROlB3OjV3MUi5OlE>
HT1080 MWHGeY5kfGmxbjDBd5NigQ>? NGrC[WsyKM7:TR?= MYmyOEBpyqB? NUmxUZRKcW6mdXPld{BiKHCxdHXueEBodG:kYXygSG5CKGSjbXHn[UBz\XOyb37z[S=> M3n5TVI2PTF6OU[x
HDFn MV;DfZRwfG:6aXPpeJkhSXO|YYm= NWjqe4p[PzJiaB?= MojwTWM2OD17LkOxKeKh NXjUTosxOjV{N{[3PVI>
THP-1 MUnDfZRwfG:6aXPpeJkhSXO|YYm= MWG3NkBp NHjnT3JKSzVyPUSuO|cm NI\ETJMzPTJ5Nke5Ni=>
HT-29 MkXvR5l1d3SxeHnjbZR6KEG|c3H5 NUnlUoNQPzJiaB?= M4f4WGlEPTB;MUGuOFkm NGjOZWQzPTJ5Nke5Ni=>
HCT116  NE\z[JFEgXSxdH;4bYNqfHliQYPzZZk> NHXO[4Y4OiCq NFz5SllKSzVyPUGxMlM1LQ>? MYSyOVI4Pjd7Mh?=
A431 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;pPGlsPTBvMkCwJGlW NXjLTZpyPDkkgJno MmDnbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> MmD6NlUyODF{OUm=
T24 MmLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXm1NE0zODBiSWW= M1LTdFQ56oDLaB?= NV7afJc1cW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? M2rVZ|I2OTBzMkm5
AY-27  NV3kfmNST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37VZ|UxNTJyMDDJWS=> NULoZ245PDkkgJno NIruToNqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 MX[yOVExOTJ7OR?=
A549 M322fWZ2dmO2aX;uJGF{e2G7 MWSxJOK2\y:vTNMg NGm5V4MxNTR6IHi= MXHpcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3dCpG9RVsLibWLORS=> MmG2NlQ6PjN4M{W=
MLE12 MmjhSpVv[3Srb36gRZN{[Xl? NFLYcXUyKML3Zz;tUOKh NIXv[5YxNTR6IHi= NFL0eZhqdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4bDqE:STtMgcXJPSQ>? M4nVc|I1QTZ|NkO1
Jurkat NUTXWZkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn34NlDjiIoQvH2= M1XRW|I16oDLaNMg NIP4WpBienKnc4TzJJRp\SClZXzsJIN6[2ynIHH0JJRp\SCJMjDwbIF{\Q>? M4DyVFI1QTF4OEmz
HeLa  NUDzZmRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjzd5l7UUN3ME2xNE4zyqEQvF2= Mo\sNlQ4OzJ|OUe=
C18-4 NXrUZZZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWWwMVExOCEQvF2= NF;GNmpqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 NGr2PXkzPDV5MUm4Ni=>
BMG-1  NUnXd4Q4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHlTo41OC96MNMg{txoN21? M1jQXlPDqGh? MW\pcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 Mn65NlM6ODZ5Mk[=
A459 M{DKSmFxd3C2b4Ppd{BCe3OjeR?= MWOxNEBuXQ>? MUS0PEBp MX\pcoR2[2W|IHHwc5B1d3Orcx?= Mn3TNlM6ODJ5Nk[=
MOCK NWS5UJVUSXCxcITvd4l{KEG|c3H5 MXuxNEBuXQ>? NUDCWHp2PDhiaB?= M2TZeYlv\HWlZYOgZZBweHSxc3nz M4q1[VI{QTB{N{[2
MMP1 Ml3iRZBweHSxc3nzJGF{e2G7 M{LsZ|ExKG2X NYfNbVZUPDhiaB?= NVTMdYExcW6mdXPld{BieG:ydH;zbZM> M{PNe|I{QTB{N{[2
A549 NUf2UHN1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGexdmszODBizszN NXXDWFMxOjRiaNMg Mknh[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIPp[45q\mmlYX70cJk> M1HIb|I{QDB3N{mz
HCT-116 M37BdmFxd3C2b4Ppd{BCe3OjeR?= MojDN{84NjVxMUWg{txoN22u MmXaOFghcA>? Mn3JdoVlfWOnczD0bIUhdGW4ZXygc4YhSkyKIHH0JIhq\2hiY3;uZ4VvfHKjdHnvci=> M4\z[VI{PzB6Nk[4
HeLa MXHBdI9xfG:|aYOgRZN{[Xl? MYCzM|cvPS9zNTFOwIcwdWx? NVj3S|B7PDhiaB?= MXry[YR2[2W|IITo[UBt\X[nbDDv[kBDVEhiYYSgbIlocCClb37j[Y51emG2aX;u NInDWXozOzdyOE[2PC=>
HCT116 NXLhNIN{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUK0SWkyOC1zMECg{txoN22u M4DUb|Q5KGh? MVrpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NWHvd2hMOjN3MUiyNFE>
NCM460 M2jTTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULsfGk4OC1zMECg{txoN22u NW[xUWFnPDhiaB?= NV7xbIJ3cW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? NFPE[IQzOzVzOEKwNS=>
NT2  NWTCPZhnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUCyOEBpyqB? MV3MSFUxRTRyMPMAjeK2\y:vbB?= NXHsT3ZkOjN|OE[0NlA>
NT2  NXjPeJRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXW0PEBp MWHMSFUxRTFyMDFCuYcwdWx? M2DWeVI{Ozh4NEKw
NT2  NX;CO4hjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfX[2U6PzJiaB?= MXnMSFUxRTJy4pEJxtVoN22u M{iz[|I{Ozh4NEKw
NT2  NUHB[XlwSXCxcITvd4l{KEG|c3H5 MmLyOFAx6oDLwsXnM41t MnLBNlQhcMLi MUTpcoR2[2W|IIPp[45q\mmlYX70JIlv[3KnYYPld{BqdiClYYPwZZNmNTNuODy5JIFkfGm4aYT5xsA> M1LLdlI{Ozh4NEKw
NTera-2 MnXJSpVv[3Srb36gRZN{[Xl? NEPFeoYyOjBizsznM41t NUHHN|l1PzJiaB?= MmTKd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiOD3pd49xem:|dHHu[UBt\X[nbIO= M2LWdlIzQDJ3M{W1
NCCIT MYfGeY5kfGmxbjDBd5NigQ>? NGrIcpYyOjBizsznM41t NX7XPGdGPzJiaB?= MXnzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyB6LXnzc5Bzd3O2YX7lJIxmfmWucx?= NWP2SXA4OjJ6MkWzOVU>
NTera-2 MlLaSpVv[3Srb36gRZN{[Xl? NF7Zd|MyOjBizsznM41t NH7DUHI4OiCq NF7NT41{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDURmFTWyCuZY\lcJM> MnvyNlI5OjV|NUW=
NCCIT M{j1U2Z2dmO2aX;uJGF{e2G7 M33MVFEzOCEQvHevcYw> NF3UOW84OiCq NULBbFVwe2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgWGJCWlNibHX2[Yx{ MoWxNlI5OjV|NUW=
NCCIT MWHGeY5kfGmxbjDBd5NigQ>? NXTKZ4lHOTJyIN88[{9udA>? MlHKO|IhcA>? MnLnd4lodmmoaXPhcpRtgSCmZXPy[YF{\XNiR2PIJIxmfmWucx?= MkPVNlI5OjV|NUW=
NTera-2 MkHYSpVv[3Srb36gRZN{[Xl? M2r3Z|EzOCEQvHevcYw> MYO3NkBp NYHncI1ne2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgVJJwfGWrbjDjZZJjd267bDDs[ZZmdHN? M3HwRlIzQDJ3M{W1
NCCIT MWPGeY5kfGmxbjDBd5NigQ>? NHLmVGcyOjBizsznM41t MXG3NkBp NWLBdXMze2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgVJJwfGWrbjDjZZJjd267bDDs[ZZmdHN? M4q2SVIzQDJ3M{W1
NTera-2 MmLKSpVv[3Srb36gRZN{[Xl? Ml[5NVIxKM7:Zz;tcC=> NVrEU5RKPzJiaB?= NXW3U5k3e2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgUHBQKGyndnXsdy=> MYCyNlgzPTN3NR?=
NCCIT Mnj4SpVv[3Srb36gRZN{[Xl? MmL3NVIxKM7:Zz;tcC=> MVq3NkBp NVfSNZFie2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgUHBQKGyndnXsdy=> MXSyNlgzPTN3NR?=
MDA-MB-468 NU\h[mY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7VTJYx6oDVMkCwxsDPxGdxbVy= MV6yOEBp NETFNmZqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 NH\NUXozOjhzOUG5Oi=>
231-H2N NXPXdHhmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LXZ|DjiJN{MEFCpO69\y:vTB?= NIDoVGczPCCq M2K3WIlvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> NI\LOFUzOjhzOUG5Oi=>
A549  M2Lx[WZ2dmO2aX;uJGF{e2G7 NIPDVIQzODBxNECwJO69VQ>? M3;tVZJme3WudIOgbY4h[SCmb4PlMZJme3CxboPpeoUhcW6lcnXhd4UhcW5iUl;T MX2yNlc4OzZ7Nx?=
A549  M2n4VGZ2dmO2aX;uJGF{e2G7 NVW4bJBKOC12MECg{txO NWLSRXVPOi12ODDo NXTrTHpV[2G3c3XzJI1wemVibYTEUmEhfGijbjDuSG5CKGSjbXHn[S=> M1\UVFIzPzd|Nkm3
A549  MlPCSpVv[3Srb36gRZN{[Xl? Mn;uNVAxKM7:TdMg NGK5SIwx6oDVNEigbC=> MWPjZZV{\XNiY3HzdIF{\S1|IHHjeIl3[XSrb36= NFy3ZY4zOjd5M{[5Oy=>
A549  NFjadWdHfW6ldHnvckBCe3OjeR?= NGi3SXUyODBizszNxsA> NY\rSIJLOOLCk{S4JIg> NHvpUoFk[XW|ZYOgVGtFOSClbHXheoFo\Q>? M{DQ[lIzPzd|Nkm3
A549  MXTGeY5kfGmxbjDBd5NigQ>? NHfHNXAyODBizszNxsA> Mln5NQKBmzR6IHi= MWDjZZV{\XNibXn0c4Npd26mcnnhcEBtd2OjbHn6ZZRqd25ib3[gRoF5 MX[yNlc4OzZ7Nx?=
A549  M4[3SGZ2dmO2aX;uJGF{e2G7 MoW3NVAxKM7:TdMg Mnn5NQKBmzR6IHi= NHXNbIhl\WO{ZXHz[ZMhVU2SIHHu[EBCXFBibHX2[Yx{ MX2yNlc4OzZ7Nx?=
MCF-7/Her-18  MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrNd5d{OC52Mj2xO|AxKM7:Zz;tUC=> NHflfnozPCCq NEn2XW1qdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 MnnyNlI3OjF2MES=
MCF-7 NWXNZ29PWESWL2DDTUBVemWjdH3lcpQ> M3;SR|AvOjVizsznM41tNg>? M3jsT|EuPCCq NYf6PFlle2ixd4Ogd4lodmmoaXPhcpQhMFEEoEygNE4xPSliY4n0c5RwgGmlIHXm[oVkfA>? MlT6NlI2QTF{OES=
MDA-MB-231 M2HGOHBFXC:SQ1mgWJJm[XSvZX70 MV2wMlI2KM7:Zz;tcE4> MVWxMVQhcA>? M{ThVZNpd3e|IIPp[45q\mmlYX70JEhRyqB:IECuNFUqKGO7dH;0c5hq[yCnZn\lZ5Q> MlfENlI2QTF{OES=
MDA-MB-235  MnvoVGRVN1CFSTDUdoVifG2nboS= NELPO|gxNjJ3IN88[{9udC5? MWmxMVQhcA>? Ml;od4hwf3Nic3nncolncWOjboSgLHDDqDxiMD6wOUkh[3m2b4TvfIlkKGWoZnXjeC=> MnPDNlI2QTF{OES=
MCF-7 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV2wMVIh|rypL33sMi=> NWXr[IRlOjRxNEigbC=> MV;FR|UxRTFwMjFOwIcwdUx? NVjJVng5OjJ3OUGyPFQ>
NCCIT  NIrhfFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojtNlDjiJNzNEFCpO69\y:vbB?= NWe1NmJLPzJiaB?= MUTMSFUxRTF{MNMg{txoN22uwrC= MUiyNlU3OjF4MB?=
NCCIT  MX7GeY5kfGmxbjDBd5NigQ>? MYm3NkBp MoHld4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiY3HzdIF{\S1|IHHjeIl3cXS7wrC= NW\qVXBnOjJ3NkKxOlA>
NCCIT  NWDIRlFzTnWwY4Tpc44hSXO|YYm= NIDsbIg4OiCq MXPzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyClYYPwZZNmNThiYXP0bZZqfHoEoB?= MYKyNlU3OjF4MB?=
NCCIT  MWnGeY5kfGmxbjDBd5NigQ>? NUS1fpY1PzJiaB?= MVvzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyClYYPwZZNmNTliYXP0bZZqfHoEoB?= MlrzNlI2PjJzNkC=
NCCIT  NH3ISVJHfW6ldHnvckBCe3OjeR?= Mon3O|IhcA>? MVfzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyCEQWigcIV3\Wx? MmPmNlI2PjJzNkC=
NCCIT  MXrGeY5kfGmxbjDBd5NigQ>? MlK1O|IhcA>? Mmq1d4lodmmoaXPhcpRtgSCmZXPy[YF{\XNidHjlJGJkdC1{IHPvcpRmdnR? MkPRNlI2PjJzNkC=
NCCIT  M3vORWZ2dmO2aX;uJGF{e2G7 M1y0ZVczKGh? M3\s[5Nq\26rZnnjZY51dHliZHXjdoVie2W|IITo[UBEgXRvYzDs[ZZmdA>? NITqOXczOjV4MkG2NC=>
HeLa NETST5BHfW6ldHnvckBCe3OjeR?= MWCzNE84OCEQvHevcYw> MWqyOOKhcA>? Mn;IbY5kemWjc3XzJJRp\SCvUl7BJIxmfmWuczDv[uKheDV|78{MRXRONHB{MdMgZY5lyqCJQVTEOFU> Mor3NlI1QDd7M{e=
MCF-7  M4\qXWZ2dmO2aX;uJGF{e2G7 M{LtTVMxNzdyIN88[{9udA>? MYmyOOKhcA>? NGPhdY1qdmO{ZXHz[ZMhfGinIH3SUmEhdGW4ZXzzJI9nyqCyNURvwKxCXE1ucEKxxsBidmUEoFfBSGQ1PQ>? MUeyNlQ5Pzl|Nx?=
HeLa MVHDfZRwfG:6aXPpeJkhSXO|YYm= M3rBTFMxNzdyIN88[{9udA>? M1T2S|I1yqCq M3PJW4lv\HWlZYOgbIlocGy7IIPp[45q\mmlYX70JIxmfmWuczDv[kBnemGpbXXueIVlKESQQTDy[Yxm[XOnIHnueI8hfGinIHP5eI9xdGG|bR?= NF\YXJgzOjR6N{mzOy=>
MCF-7  NFzXVFFEgXSxdH;4bYNqfHliQYPzZZk> MWSzNE84OCEQvHevcYw> NUG4dJlqOjUEoHi= M3L0dYlv\HWlZYOgbIlocGy7IIPp[45q\mmlYX70JIxmfmWuczDv[kBnemGpbXXueIVlKESQQTDy[Yxm[XOnIHnueI8hfGinIHP5eI9xdGG|bR?= MkjuNlI1QDd7M{e=
NT2 MmGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETvcWoyODBvNkCwxsDPxGdxbXy= NX;Se|EyOjRiaB?= M1XPWGlEPTB;NECwJOK2\y:vbB?= NUnheFhuOjJ2Nkm5OVI>
NT2 NHSyeYRHfW6ldHnvckBCe3OjeR?= NFPnfWg1ODEEoN88[{9udA>? NWrw[JZ2OjRiaB?= MV;zbYdvcW[rY3HueIx6KGmwY4LlZZNmeyClYYPwZZNmNTNuODy5JIFkfGm4aYT5xsA> M4fDelIzPDZ7OUWy
NT2 NGXnVXFHfW6ldHnvckBCe3OjeR?= M{\SelQxOMLizsznM41t NYfFOGs4OjRiaB?= M1ft[JNq\26rZnnjZY51dHliaX7jdoVie2W|IFLBXEBt\X[nbB?= M1W0XVIzPDZ7OUWy
NT2 MYTGeY5kfGmxbjDBd5NigQ>? MlHuOFAxyqEQvHevcYw> MXmyOEBp MUnzbYdvcW[rY3HueIx6KGSnY4LlZZNmeyCEY3ytNkBt\X[nbB?= NVn6R4ZiOjJ2Nkm5OVI>
CHO NWfOUJhbTnWwY4Tpc44hSXO|YYm= NXrxb|BJOi53wrFOwIcwdWx? NXXCOZNzOThiaD:2JIQ> NVXuT4xncW6mdXPld:KheGW{c3nzeIVv[2Vib3[gZ4hzd22xc3;t[UBl[W2jZ3W= NWLKTHhVOjJ{M{CxPVU>
Jurkat MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NICwZVAxNTFyMNMg{txoN22u NFjIZlgzPCCq M1Pu[YFzemW|dIOgeIhmKGOnbHygZ5lkdGViYYSgeIhmKEd{IIDoZZNm M{\YflIzOjJ|M{Oy
Jurkat M3fLemZ2dmO2aX;uJGF{e2G7 NVzmVmRNOzEEoN88[{9udA>? NWHqOW5nOjRiaB?= NX;UOoFNcW6lcnXhd4V{KHSqZTDwdo91\WmwIHzleoVteyCxZjDjfYNtcW6|IFSzMEBCKGGwZDDCNS=> MmLmNlIzOjN|M{K=
Jurkat NV75W4tmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NED5O3QxNTFyMNMg{txoN22u Mnj2NlQhcA>? NHzkNYdqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZIhf2m2aDDhckBKSzVyII\hcJVmKG:oIEGwNO69\y:vTB?= MUOyNlIzOzN|Mh?=
Jurkat M{XXTmZ2dmO2aX;uJGF{e2G7 M2e1SlMxyqEQvHevcYw> MXOyOEBp MU\pcoNz\WG|ZYOgeIhmKGWoZnXjeEBw\iCyeXPubYRqd26nIH;uJJBpd3OyaH;yfYxifGmxbjDs[ZZmdHNib3[gbIl{fG:wZTDINmEvYA>? NIj4V5czOjJ{M{OzNi=>
U2OS EGFPnls NFnEWJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnDNE0zyqEQvHevcYw> MXeyOEBp NHKzR3NqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 NUTDRWFzOjF6MUGwNFc>
U2OS KuEnls NUC3e|ViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\KNE0zyqEQvHevcYw> MVGyOEBp M3LnNIlvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> NFvtWZMzOThzMUCwOy=>
MCF-7 M4XPVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnENE01ODBizszN NYrTe3pPPzJiaB?= M4C2XmxEPTB;MUWxMljDqM7:TR?= M2i3[VIyPzB|Mkmx
MCF-7/Adr  MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIGzU2MxNTRyMDFOwG0> MW[3NkBp M3vOcWxEPTB;NUiuOeKh|ryPwrC= NFLkcFUzOTdyM{K5NS=>
WI-38 NIO4TY1HfW6ldHnvckBCe3OjeR?= NWDzb4xTOC92MD:4NQKBkc7:Zz;tcOKh M3KwVVMhcA>? M3rnXIlv\HWlZYOgZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDpcoNz\WG|ZTDpckB1cGViTV6g[pJmeXWnbnP5xsA> MoT2NlE2QTl4MUK=
hBMSC MXvGeY5kfGmxbjDBd5NigQ>? NEDYbnUxNzRyL{iw5qCK|rypL33sxsA> M3HJcFMhcA>? MkTMbY5lfWOnczDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IHnuZ5Jm[XOnIHnuJJRp\SCPTjDmdoVyfWWwY4pCpC=> MVKyNVU6QTZzMh?=
NCI-H23 Ml;USpVv[3Srb36gRZN{[Xl? Mme5NE81OC96MPMAje69\y:vbNMg M4Xoe|MhcA>? NWr6cY5zcW6mdXPld{BiKGOxbnPlcpRz[XSrb36t[IVx\W6mZX70JIlv[3KnYYPlJIlvKHSqZTDNUkBnemWzdXXuZ5nDqA>? NIK3OnQzOTV7OU[xNi=>
A-549 Mn22SpVv[3Srb36gRZN{[Xl? MWCwM|QxNzhy4pEJ{txoN22uwrC= M4fuSlMhcA>? MVLpcoR2[2W|IHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRiaX7jdoVie2ViaX6geIhmKE2QIH\y[ZF2\W6ledMg Mk\XNlE2QTl4MUK=
PBL  NWD4eWVCTnWwY4Tpc44hSXO|YYm= NYHxO3JNOC92MD:4NQKBkc7:Zz;tcOKh NU\vU5NIOyCq M3HmWYlv\HWlZYOgZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDpcoNz\WG|ZTDpckB1cGViTV6g[pJmeXWnbnP5xsA> NFPSbGIzOTV7OU[xNi=>
pol β −/− MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvVNE4zPS1{MEFCpO69\y:vbB?= MorONlTDqGh? Mlnj[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIfpeIghcW6lcnXhd4lv\yClb37j[Y51emG2aX;ud:Kh M3\TRlIyOjVzOUS0
pol β +/+ NVHC[2dQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkP0NE4zPS1{MEFCpO69\y:vbB?= M4HxeVI1yqCq MXrk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHlid3n0bEBqdmO{ZXHzbY5oKGOxbnPlcpRz[XSrb37zxsA> M1K3c|IyOjVzOUS0
pol β −/− M3PaOmZ2dmO2aX;uJGF{e2G7 MXKwMVIvPSEQvHevcYw> MYWyJIg> NX;LUVg{[2G3c3XzJGRPSSCmYX3h[4U> Mln3NlEzPTF7NES=
pol β +/+ M1LzdGZ2dmO2aX;uJGF{e2G7 MV2wMVIvPSEQvHevcYw> M{LLeVIhcA>? MlHKZ4F2e2W|IFTORUBl[W2jZ3W= MmDtNlEzPTF7NES=
pol β −/− M{HZO2Z2dmO2aX;uJGF{e2G7 MkXFNE02KM7:Zz;tcC=> Mn\HOFghcA>? NV3iOWhS[2G3c3XzJI1q[3KxboXjcIV2eyCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueIx6 NGrFSpAzOTJ3MUm0OC=>
pol β +/+ M{LzVmZ2dmO2aX;uJGF{e2G7 NGXMeY4xNTVizsznM41t MWC0PEBp MXXjZZV{\XNibXnjdo9vfWOuZYXzJIRwe2ViYX7kJJRqdWViZHXw[Y5l\W62bIm= MWeyNVI2OTl2NB?=
TK6  NXHCOpF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXuyOU0yPTBizsznM41t MkXEPVYhcA>? NWGxOHNlcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? NYOzcFRXOjFyOEG0PFc>
TK6  sLUC+Apn1 NXrxbnNET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPjNlUuOTVyIN88[{9udA>? NW\EWmJqQTZiaB?= MWPpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NEjyfHAzOTB6MUS4Oy=>
TK6 sAPE1+Apn1 MmmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HCOFI2NTF3MDFOwIcwdWx? NYfNb5FoQTZiaB?= M2DpTZNq\26rZnnjZY51dHliaX7obYJqfHNiY3XscEBoem:5dHig[I9{\SCmZYDlcoRmdnSueR?= NYP1ZYsxOjFyOEG0PFc>
HCT116 NHS4fIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XMb|I2NTF3MDFOwIcwdWx? M{jtfVk3KGh? NFTScI5qdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 MkHUNlExQDF2OEe=
HCT116 sLUC+Apn1 NW[xZlRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXWyOU0yPTBizsznM41t Mor5PVYhcA>? MlXzbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> M3HpblIyODhzNEi3
HCT116 sAPE1+Apn1 NYGzVY5WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfZPGFoOjVvMUWwJO69\y:vbB?= Mk\pPVYhcA>? NF3nZnl{cWewaX\pZ4FvfGy7IHnubIljcXS|IHPlcIwh\3Kxd4ToJIRwe2ViZHXw[Y5l\W62bIm= MkDpNlExQDF2OEe=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
LRP6 / Wnt5AB / Dvl2 / β-catenin; 

PubMed: 27649046     


CRL-1490 cells were treated with the indicated concentrations of bleomycin for either 12 or 24 h, and then probed for canonical Wnt proteins LRP6, Wnt5AB, Dvl2, and β-catenin. 

phospho-eIF2α / eIF2α; 

PubMed: 23762310     


Western blotting analysis of phosphorylated, total eIF2α and β-actin in CT26 treated 24 h with the indicated drugs. BLM: Bleomycin

cytochrome c; 

PubMed: 20154224     


mitochondrial release of cytochrome c was detected by Western blot in cytosolic extract and analyzed by band densitometry. Data show the means of four independent experiments ± SE. *Statistical significance from control, P < 0.05. Representative Western blots are shown.

Bcl-xl; 

PubMed: 20154224     


Representative Western blots are shown of whole cell extract using anti-Bcl-xL.

Bcl-2; 

PubMed: 20154224     


Representative Western blots are shown of whole cell extract using anti-Bcl-2.

27649046 23762310 20154224
Immunofluorescence
LC3; 

PubMed: 23762310     


CT26 cells were cultured on glass slides and treated with indicated drugs for 24 h. The cells were then submitted to anti-LC3 (green) and DAPI (blue) labeling and observed under an epifluorescence microscope. BLM: Bleomycin

23762310
ELISA
HMGB1; 

PubMed: 23762310     


HMGB1 was titrated with ELISA method in supernatant of CT26 cells treated 24 h with indicated drugs. BLM: Bleomycin

23762310
In vivo Day 7 post-Bleomycin sulfate, CD45+ cells in BALf in NOX-/- is 1.7-fold > WT, 57% of which are Mf that decreases by 67% in WT and 83% in NOX-/- by Day 21. [5]

Protocol

Cell Research:

[4]

- Collapse
  • Cell lines: ADIPO-P2 cells
  • Concentrations: 2.5 μg/mL
  • Incubation Time: 30 minutes
  • Method:

    ADIPO-P2 cells are grown in D-MEM high glucose medium supplemented with 20% fetal calf serum, penicillin (100 U/mL) and streptomycin (100 μg/mL) at 37 °C and 5% CO2 atmosphere. Cells are cultured as monolayer in TC25 Corning flasks containing 1.5 × 105 cells/mL. For each experiment, two flasks are set up, one for the control and one for the treated culture. During the log phase of growth ADIPO-P2 cells are treated with a 30 minutes pulse of 2.5 μg/mL of Bleomycin sulfate. Control cultures are set up in parallel but not exposed to Bleomycin sulfate. Time of exposure and concentration of Bleomycin sulfate are chosen according to previous studies carried out in our laboratory with mammalian cells exposed to Bleomycin sulfate. At the end of the pulse treatment with Bleomycin sulfate, the cells are washed twice with Hank's balanced salt solution and kept in culture with fresh culture medium until harvesting. Cells are continuously maintained in culture during 5 passages or subcultures after treatment. Subcultivation is carried out whenever the cultures became confluent (approximately 4 × 105 cells/mL of culture medium). To estimate cell growth, at the time of subcultivation cells are collected by trypsinization, an aliquot of about 200 μL stained with 0.4% trypan blue, and the number of viable cells is determined. Cells are then suspended in fresh culture medium and dispensed into new culture flasks containing 1 × 105 cells/mL to continue growing. The rest of the cells is discarded or dispensed in another flask for cytogenetic analysis, which is performed at 18 hours and 10 days after the end of treatments. To analyze chromosomal aberrations, colchicine (0.1 μg/mL) is added to cell cultures during the last 3 hours of culture. Chromosome preparations are made following standard procedures. After harvesting, cells are hypotonically shocked, fixed in methanol:acetic acid (3:1), spread onto glass slides and processed for PNA-FISH. Two independent experiments are carried out.


    (Only for Reference)
Animal Research:

[7]

- Collapse
  • Animal Models: CD-1 mice
  • Dosages: 5 mg/kg, 2 ml/kg
  • Administration: Administered via i.t.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL warmed (66.11 mM)
Water 100 mg/mL (66.11 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 1512.62
Formula

C55H85N17O25S4

CAS No. 9041-93-4
Storage powder
in solvent
Synonyms NSC125066
Smiles CC(O)C(NC(=O)C(C)C(O)C(C)NC(=O)C(NC(=O)C1=C(C)C(=NC(=N1)C(CC(N)=O)NCC(N)C(N)=O)N)C(OC2OC(CO)C(O)C(O)C2OC3OC(CO)C(O)C(OC(N)=O)C3O)C4=C[NH]C=N4)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C.O[S]([O-])

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    what is the ratio between bleomycin A2 and bleomycin B2 in your product?

  • Answer:

    The content of Bleomycin A2 and Bleomycin B2 is 62% and 29% respectively.

Tags: buy Bleomycin Sulfate | Bleomycin Sulfate ic50 | Bleomycin Sulfate price | Bleomycin Sulfate cost | Bleomycin Sulfate solubility dmso | Bleomycin Sulfate purchase | Bleomycin Sulfate manufacturer | Bleomycin Sulfate research buy | Bleomycin Sulfate order | Bleomycin Sulfate mouse | Bleomycin Sulfate chemical structure | Bleomycin Sulfate mw | Bleomycin Sulfate molecular weight | Bleomycin Sulfate datasheet | Bleomycin Sulfate supplier | Bleomycin Sulfate in vitro | Bleomycin Sulfate cell line | Bleomycin Sulfate concentration | Bleomycin Sulfate nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID